The serotonin syndrome scale: first results on validity
As a modification of the diagnostic criteria of the serotonin syndrome proposed by Sternbach, we developed the Serotonin syndrome scale for the operationalized assessment of both the presence and the severity of the core symptoms of the serotonin syndrome. In a first study on the validity of this sc...
Gespeichert in:
| Veröffentlicht in: | European archives of psychiatry and clinical neuroscience 1998-05, Vol.248 (2), p.96-103 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 103 |
|---|---|
| container_issue | 2 |
| container_start_page | 96 |
| container_title | European archives of psychiatry and clinical neuroscience |
| container_volume | 248 |
| creator | Hegerl, U Bottlender, R Gallinat, J Kuss, H J Ackenheil, M Möller, H J |
| description | As a modification of the diagnostic criteria of the serotonin syndrome proposed by Sternbach, we developed the Serotonin syndrome scale for the operationalized assessment of both the presence and the severity of the core symptoms of the serotonin syndrome. In a first study on the validity of this scale, the relationships between the serotonin syndrome score (SSS) and both the paroxetine plasma levels (n = 42) and the loudness dependence of the auditory evoked potentials (LDAEP; n = 24) were investigated in depressed patients treated with paroxetine. A strong LDAEP is supposed to indicate low central serotonergic neurotransmission, and vice versa. The SSS was positively related to paroxetine plasma levels and negatively to the LDAEP. Both results support the validity of the serotonin syndrome scale. Using a SSS > 6 as diagnostic criterion, mild serotonin syndromes were diagnosed in 5 of our 42 patients. The Serotonin syndrome scale may become a useful tool for clinicians and scientists dealing with the serotonin syndrome. |
| doi_str_mv | 10.1007/s004060050024 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1434034180</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1434034180</sourcerecordid><originalsourceid>FETCH-LOGICAL-c374t-8f429ff23e1ed305773bda1dee8685768ccde918829078e20b01e9eff7c820ea3</originalsourceid><addsrcrecordid>eNpd0E1LAzEQBuAgSq3Vo0dhwYuX1cnHbhJvUvyCgpd6XtLNBLfsbmqyK_Tfm9oi6GlgeHiZeQm5pHBLAeRdBBBQAhQATByRKRWc50poekymoAXklHNxSs5iXAMALRhMyESXO6GnRC4_MIsY_OD7ps_itrfBd2lVmxbvM9eEOGQB49gOMfN99mXaxjbD9pycONNGvDjMGXl_elzOX_LF2_Pr_GGR11yKIVdOMO0c40jRciik5CtrqEVUpSpkqeraoqZKMQ1SIYMVUNTonKwVAzR8Rm72uZvgP0eMQ9U1sca2NT36MVbpWwFcUAWJXv-jaz-GPl2XFJPJFT8q36s6-BgDumoTms6EbUWh2hVa_Sk0-atD6rjq0P7qQ4P8G60bboY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1427340580</pqid></control><display><type>article</type><title>The serotonin syndrome scale: first results on validity</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Hegerl, U ; Bottlender, R ; Gallinat, J ; Kuss, H J ; Ackenheil, M ; Möller, H J</creator><creatorcontrib>Hegerl, U ; Bottlender, R ; Gallinat, J ; Kuss, H J ; Ackenheil, M ; Möller, H J</creatorcontrib><description>As a modification of the diagnostic criteria of the serotonin syndrome proposed by Sternbach, we developed the Serotonin syndrome scale for the operationalized assessment of both the presence and the severity of the core symptoms of the serotonin syndrome. In a first study on the validity of this scale, the relationships between the serotonin syndrome score (SSS) and both the paroxetine plasma levels (n = 42) and the loudness dependence of the auditory evoked potentials (LDAEP; n = 24) were investigated in depressed patients treated with paroxetine. A strong LDAEP is supposed to indicate low central serotonergic neurotransmission, and vice versa. The SSS was positively related to paroxetine plasma levels and negatively to the LDAEP. Both results support the validity of the serotonin syndrome scale. Using a SSS > 6 as diagnostic criterion, mild serotonin syndromes were diagnosed in 5 of our 42 patients. The Serotonin syndrome scale may become a useful tool for clinicians and scientists dealing with the serotonin syndrome.</description><identifier>ISSN: 0940-1334</identifier><identifier>EISSN: 1433-8491</identifier><identifier>DOI: 10.1007/s004060050024</identifier><identifier>PMID: 9684919</identifier><language>eng</language><publisher>Germany: Springer Nature B.V</publisher><subject>Adult ; Aged ; Antidepressants ; Antidepressive Agents, Second-Generation - administration & dosage ; Antidepressive Agents, Second-Generation - adverse effects ; Antidepressive Agents, Second-Generation - pharmacokinetics ; Depressive Disorder - drug therapy ; Depressive Disorder - physiopathology ; Drug overdose ; Evoked Potentials, Auditory - drug effects ; Female ; Humans ; Male ; Middle Aged ; Nervous System Diseases - chemically induced ; Nervous System Diseases - physiopathology ; Neurologic Examination - statistics & numerical data ; Paroxetine - administration & dosage ; Paroxetine - adverse effects ; Paroxetine - pharmacokinetics ; Reproducibility of Results ; Serotonin ; Serotonin - physiology ; Serotonin Uptake Inhibitors - administration & dosage ; Serotonin Uptake Inhibitors - adverse effects ; Serotonin Uptake Inhibitors - pharmacokinetics ; Synaptic Transmission - drug effects ; Synaptic Transmission - physiology ; Syndrome ; Validity</subject><ispartof>European archives of psychiatry and clinical neuroscience, 1998-05, Vol.248 (2), p.96-103</ispartof><rights>Springer-Verlag Berlin Heidelberg 1998</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c374t-8f429ff23e1ed305773bda1dee8685768ccde918829078e20b01e9eff7c820ea3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9684919$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hegerl, U</creatorcontrib><creatorcontrib>Bottlender, R</creatorcontrib><creatorcontrib>Gallinat, J</creatorcontrib><creatorcontrib>Kuss, H J</creatorcontrib><creatorcontrib>Ackenheil, M</creatorcontrib><creatorcontrib>Möller, H J</creatorcontrib><title>The serotonin syndrome scale: first results on validity</title><title>European archives of psychiatry and clinical neuroscience</title><addtitle>Eur Arch Psychiatry Clin Neurosci</addtitle><description>As a modification of the diagnostic criteria of the serotonin syndrome proposed by Sternbach, we developed the Serotonin syndrome scale for the operationalized assessment of both the presence and the severity of the core symptoms of the serotonin syndrome. In a first study on the validity of this scale, the relationships between the serotonin syndrome score (SSS) and both the paroxetine plasma levels (n = 42) and the loudness dependence of the auditory evoked potentials (LDAEP; n = 24) were investigated in depressed patients treated with paroxetine. A strong LDAEP is supposed to indicate low central serotonergic neurotransmission, and vice versa. The SSS was positively related to paroxetine plasma levels and negatively to the LDAEP. Both results support the validity of the serotonin syndrome scale. Using a SSS > 6 as diagnostic criterion, mild serotonin syndromes were diagnosed in 5 of our 42 patients. The Serotonin syndrome scale may become a useful tool for clinicians and scientists dealing with the serotonin syndrome.</description><subject>Adult</subject><subject>Aged</subject><subject>Antidepressants</subject><subject>Antidepressive Agents, Second-Generation - administration & dosage</subject><subject>Antidepressive Agents, Second-Generation - adverse effects</subject><subject>Antidepressive Agents, Second-Generation - pharmacokinetics</subject><subject>Depressive Disorder - drug therapy</subject><subject>Depressive Disorder - physiopathology</subject><subject>Drug overdose</subject><subject>Evoked Potentials, Auditory - drug effects</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Nervous System Diseases - chemically induced</subject><subject>Nervous System Diseases - physiopathology</subject><subject>Neurologic Examination - statistics & numerical data</subject><subject>Paroxetine - administration & dosage</subject><subject>Paroxetine - adverse effects</subject><subject>Paroxetine - pharmacokinetics</subject><subject>Reproducibility of Results</subject><subject>Serotonin</subject><subject>Serotonin - physiology</subject><subject>Serotonin Uptake Inhibitors - administration & dosage</subject><subject>Serotonin Uptake Inhibitors - adverse effects</subject><subject>Serotonin Uptake Inhibitors - pharmacokinetics</subject><subject>Synaptic Transmission - drug effects</subject><subject>Synaptic Transmission - physiology</subject><subject>Syndrome</subject><subject>Validity</subject><issn>0940-1334</issn><issn>1433-8491</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNpd0E1LAzEQBuAgSq3Vo0dhwYuX1cnHbhJvUvyCgpd6XtLNBLfsbmqyK_Tfm9oi6GlgeHiZeQm5pHBLAeRdBBBQAhQATByRKRWc50poekymoAXklHNxSs5iXAMALRhMyESXO6GnRC4_MIsY_OD7ps_itrfBd2lVmxbvM9eEOGQB49gOMfN99mXaxjbD9pycONNGvDjMGXl_elzOX_LF2_Pr_GGR11yKIVdOMO0c40jRciik5CtrqEVUpSpkqeraoqZKMQ1SIYMVUNTonKwVAzR8Rm72uZvgP0eMQ9U1sca2NT36MVbpWwFcUAWJXv-jaz-GPl2XFJPJFT8q36s6-BgDumoTms6EbUWh2hVa_Sk0-atD6rjq0P7qQ4P8G60bboY</recordid><startdate>19980501</startdate><enddate>19980501</enddate><creator>Hegerl, U</creator><creator>Bottlender, R</creator><creator>Gallinat, J</creator><creator>Kuss, H J</creator><creator>Ackenheil, M</creator><creator>Möller, H J</creator><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope></search><sort><creationdate>19980501</creationdate><title>The serotonin syndrome scale: first results on validity</title><author>Hegerl, U ; Bottlender, R ; Gallinat, J ; Kuss, H J ; Ackenheil, M ; Möller, H J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c374t-8f429ff23e1ed305773bda1dee8685768ccde918829078e20b01e9eff7c820ea3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antidepressants</topic><topic>Antidepressive Agents, Second-Generation - administration & dosage</topic><topic>Antidepressive Agents, Second-Generation - adverse effects</topic><topic>Antidepressive Agents, Second-Generation - pharmacokinetics</topic><topic>Depressive Disorder - drug therapy</topic><topic>Depressive Disorder - physiopathology</topic><topic>Drug overdose</topic><topic>Evoked Potentials, Auditory - drug effects</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Nervous System Diseases - chemically induced</topic><topic>Nervous System Diseases - physiopathology</topic><topic>Neurologic Examination - statistics & numerical data</topic><topic>Paroxetine - administration & dosage</topic><topic>Paroxetine - adverse effects</topic><topic>Paroxetine - pharmacokinetics</topic><topic>Reproducibility of Results</topic><topic>Serotonin</topic><topic>Serotonin - physiology</topic><topic>Serotonin Uptake Inhibitors - administration & dosage</topic><topic>Serotonin Uptake Inhibitors - adverse effects</topic><topic>Serotonin Uptake Inhibitors - pharmacokinetics</topic><topic>Synaptic Transmission - drug effects</topic><topic>Synaptic Transmission - physiology</topic><topic>Syndrome</topic><topic>Validity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hegerl, U</creatorcontrib><creatorcontrib>Bottlender, R</creatorcontrib><creatorcontrib>Gallinat, J</creatorcontrib><creatorcontrib>Kuss, H J</creatorcontrib><creatorcontrib>Ackenheil, M</creatorcontrib><creatorcontrib>Möller, H J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><jtitle>European archives of psychiatry and clinical neuroscience</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hegerl, U</au><au>Bottlender, R</au><au>Gallinat, J</au><au>Kuss, H J</au><au>Ackenheil, M</au><au>Möller, H J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The serotonin syndrome scale: first results on validity</atitle><jtitle>European archives of psychiatry and clinical neuroscience</jtitle><addtitle>Eur Arch Psychiatry Clin Neurosci</addtitle><date>1998-05-01</date><risdate>1998</risdate><volume>248</volume><issue>2</issue><spage>96</spage><epage>103</epage><pages>96-103</pages><issn>0940-1334</issn><eissn>1433-8491</eissn><abstract>As a modification of the diagnostic criteria of the serotonin syndrome proposed by Sternbach, we developed the Serotonin syndrome scale for the operationalized assessment of both the presence and the severity of the core symptoms of the serotonin syndrome. In a first study on the validity of this scale, the relationships between the serotonin syndrome score (SSS) and both the paroxetine plasma levels (n = 42) and the loudness dependence of the auditory evoked potentials (LDAEP; n = 24) were investigated in depressed patients treated with paroxetine. A strong LDAEP is supposed to indicate low central serotonergic neurotransmission, and vice versa. The SSS was positively related to paroxetine plasma levels and negatively to the LDAEP. Both results support the validity of the serotonin syndrome scale. Using a SSS > 6 as diagnostic criterion, mild serotonin syndromes were diagnosed in 5 of our 42 patients. The Serotonin syndrome scale may become a useful tool for clinicians and scientists dealing with the serotonin syndrome.</abstract><cop>Germany</cop><pub>Springer Nature B.V</pub><pmid>9684919</pmid><doi>10.1007/s004060050024</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0940-1334 |
| ispartof | European archives of psychiatry and clinical neuroscience, 1998-05, Vol.248 (2), p.96-103 |
| issn | 0940-1334 1433-8491 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1434034180 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adult Aged Antidepressants Antidepressive Agents, Second-Generation - administration & dosage Antidepressive Agents, Second-Generation - adverse effects Antidepressive Agents, Second-Generation - pharmacokinetics Depressive Disorder - drug therapy Depressive Disorder - physiopathology Drug overdose Evoked Potentials, Auditory - drug effects Female Humans Male Middle Aged Nervous System Diseases - chemically induced Nervous System Diseases - physiopathology Neurologic Examination - statistics & numerical data Paroxetine - administration & dosage Paroxetine - adverse effects Paroxetine - pharmacokinetics Reproducibility of Results Serotonin Serotonin - physiology Serotonin Uptake Inhibitors - administration & dosage Serotonin Uptake Inhibitors - adverse effects Serotonin Uptake Inhibitors - pharmacokinetics Synaptic Transmission - drug effects Synaptic Transmission - physiology Syndrome Validity |
| title | The serotonin syndrome scale: first results on validity |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T20%3A22%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20serotonin%20syndrome%20scale:%20first%20results%20on%20validity&rft.jtitle=European%20archives%20of%20psychiatry%20and%20clinical%20neuroscience&rft.au=Hegerl,%20U&rft.date=1998-05-01&rft.volume=248&rft.issue=2&rft.spage=96&rft.epage=103&rft.pages=96-103&rft.issn=0940-1334&rft.eissn=1433-8491&rft_id=info:doi/10.1007/s004060050024&rft_dat=%3Cproquest_cross%3E1434034180%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1427340580&rft_id=info:pmid/9684919&rfr_iscdi=true |